Journal
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
Volume 19, Issue 7, Pages 889-897Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14787210.2021.1860020
Keywords
COVID-19; repurposing of drugs; SARS-CoV-2; pathogen-centric; host-centric
Ask authors/readers for more resources
In the current global scenario, COVID-19 caused by SARS-CoV-2 remains a major clinical and public health issue with no approved efficient therapeutics. FDA approved broad-spectrum drugs/molecules are being repurposed in clinical trials for potential management of the pandemic. Expert opinions suggest repurposing pathogen-centric, host-centric, dual sword, and combinatorial drugs as potential options for effective management of COVID-19 patients.
Introduction: In the current scenario, COVID-19 is a clinical and public health problem globally. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) remains the causative agent, emerged in China and continuously spreading across the globe. Until now, no efficient therapeutics have been approved, which combat COVID-19. FDA approved broad-spectrum drugs/molecules could be repurposed against the COVID-19 and are under clinical trials, if the outcome of these trials proves positive, it could be used to manage COVID-19 pandemic. Areas covered: This article reviews the FDA approved drugs/molecules which could be repurposed in the combination or single to combat the COVID-19. Expert opinion: In this focused review, we suggested the repurposing of the pathogen-centric, host-centric, dual sword (act as pathogen-centric as well as host-centric), and the combinatorial (pathogen and host-centric) drugs against COVID-19 patients. These drugs singly or in combination could be effective for the management of COVID-19.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available